FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA OKs Blood Cancer Drug Tregzi

[ Price : $8.95]

FDA approves Orca Biosystems Tregzi to improve chronic graft-versus-host disease (GVHD)-free survival in adults with blood cancers...

CGMP Issues at Indias Wizcure Pharmaa

[ Price : $8.95]

FDA warns Indias Wizcure Pharmaa about CGMP violations in its production of over-the-counter drugs.

Chinese Drug Firm Refuses FDA Record Request

[ Price : $8.95]

FDA warns Chinas Yangzhou Hongshengding Chemical Co. about not responding to agency requests for records on its over-the-counter d...

CBER SOPP on Implementing, Managing REMS

[ Price : $8.95]

CBER publishes a Standard Operating Policy and Procedure on implementing and maintaining REMS.

FDA Novel Drug Approvals Remain Steady in 2026 First Half

[ Price : $8.95]

FDA approval numbers show it approved 23 novel drugs during the first six months of 2026, maintaining a pace that would be consist...

Complete Response on Liver Imaging Agent

[ Price : $8.95]

FDA sends Ascelia Pharma a Complete Response Letter regarding its NDA for Orviglance, a contrast agent for liver imaging.

BMC Medical Selling Adulterated, Misbranded CPAPs: FDA

[ Price : $8.95]

FDA warns Chinas BMC Medical that it is marketing adulterated and misbranded ventilators in the U.S. without an approved PMA in pl...

FDA OKs Casgevy for Younger Children

[ Price : $8.95]

FDA approves an expanded age indication for Vertex Pharmaceuticals sickle cell drug Casgevy.

Quality System, Other Violations at 3B Medical

[ Price : $8.95]

FDA warns 3B Medical about multiple violations in its work manufacturing a software device used with ventilator systems imported f...

AseptiKits Marketing Adulterated, Misbranded Devices: FDA

[ Price : $8.95]

FDA warns AseptiKits it is manufacturing and marketing adulterated and misbranded PALA Your Tears medical devices.